Integra Lifesciences Holdings Corp (NASDAQ:IART) has been downgraded to Hold in a statement by TheStreet earlier today.
- Updated: October 3, 2016
TheStreet has downgraded Integra Lifesciences Holdings Corp (NASDAQ:IART) to Hold in a statement released on 9/30/2016.
On 07/29/2016, Barclays Capital released a statement for Integra Lifesciences Holdings Corp (NASDAQ:IART) bumped up the target price from $77.00 to $84.00 that suggested a downside of 0.00%.
Boasting a price of $82.56, Integra Lifesciences Holdings Corp (NASDAQ:IART) traded 0.70% higher on the day. With the last stock price close up 7.81% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Integra Lifesciences Holdings Corp has recorded a 50-day average of $85.68 and a two hundred day average of $77.11. Volume of trade was up over the average, with 550,966 shares of IART changing hands over the typical 287,147
With a total market value of $0, Integra Lifesciences Holdings Corp has price-earnings ratio of 343.51 with a one year low of $54.75 and a one year high of $88.86 .
A total of 11 brokerages have reported on the stock. 6 brokers rating the stock a strong buy, three equity analysts rating the company a buy, six brokerages rating the company a hold, zero analysts rating the stock a underperform, and finally 0 equity analysts rating the company a sell with a one year target of $80.27.
Brief Synopsis About Integra Lifesciences Holdings Corp (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.